Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Short term Debt (2016 - 2025)

Abeona Therapeutics has reported Short term Debt over the past 11 years, most recently at $12.2 million for Q4 2025.

  • Quarterly results put Short term Debt at $12.2 million for Q4 2025, up 106.24% from a year ago — trailing twelve months through Dec 2025 was $12.2 million (up 106.24% YoY), and the annual figure for FY2025 was $12.2 million, up 106.24%.
  • Short term Debt for Q4 2025 was $12.2 million at Abeona Therapeutics, up from $8.9 million in the prior quarter.
  • Over the last five years, Short term Debt for ABEO hit a ceiling of $20.0 million in Q3 2021 and a floor of $549000.0 in Q1 2021.
  • Median Short term Debt over the past 4 years was $4.9 million (2022), compared with a mean of $6.3 million.
  • Peak annual rise in Short term Debt hit 1037.66% in 2021, while the deepest fall reached 98.04% in 2021.
  • Abeona Therapeutics' Short term Debt stood at $4.6 million in 2021, then rose by 7.0% to $4.9 million in 2022, then increased by 20.42% to $5.9 million in 2024, then soared by 106.24% to $12.2 million in 2025.
  • The last three reported values for Short term Debt were $12.2 million (Q4 2025), $8.9 million (Q3 2025), and $5.6 million (Q2 2025) per Business Quant data.